According to a new report LAMEA Continuous Glucose Monitoring Device Market, published by KBV research, the LAMEA Continuous Glucose Monitoring Device Market would witness market growth of 13.4% CAGR during the forecast period (2020-2026).
The Brazil market dominated the LAMEA Hospitals Continuous Glucose Monitoring Device Market by Country in 2019, thereby, achieving a market value of $64.6 million by 2026. The Argentina market would witness a CAGR of 14.3% during (2020 - 2026). Additionally, The UAE market is exhibiting a CAGR of 13.3% during (2020 - 2026).
The Sensors market dominated the Saudi Arabia Continuous Glucose Monitoring Device Market by Component in 2019, growing at a CAGR of 13.5 % during the forecast period. The Transmitters market would showcase a CAGR of 14.6% during (2020 - 2026). Additionally, The Receivers market is estimated to grow at highest CAGR of 15.4% during (2020 - 2026).
The Homecare Settings market dominated the South Africa Continuous Glucose Monitoring Device Market by End-user in 2019, growing at a CAGR of 13.8 % during the forecast period. The Hospitals market is anticipated to grow at a CAGR of 14.5% during (2020 - 2026). The Other End Users market is expected to witness a CAGR of 15.1% during (2020 - 2026).
Structural Insights: https://www.kbvresearch.com/lamea-continuous-glucose-monitoring-device-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson.
By Component
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
